350
Participants
Start Date
May 14, 2025
Primary Completion Date
December 31, 2029
Study Completion Date
December 31, 2029
APG777
APG777 subcutaneous injection
APG777
APG777 subcutaneous injection every 12 weeks
APG777
APG777 subcutaneous injection every 24 weeks
NOT_YET_RECRUITING
Investigational Site, Wilmington
RECRUITING
Investigational Site, Margate
RECRUITING
Investigational Site, Coral Gables
RECRUITING
Investigational Site, Nashville
NOT_YET_RECRUITING
Investigational Site, Boardman
RECRUITING
Investigational Site, Mason
RECRUITING
Investigational Site, Troy
NOT_YET_RECRUITING
Investigational Site, Detroit
NOT_YET_RECRUITING
Investigational Site, Frisco
RECRUITING
Investigational Site, San Antonio
RECRUITING
Investigational Site, Fountain Valley
NOT_YET_RECRUITING
Investigational Site, Portland
NOT_YET_RECRUITING
Investigational Site, Calgary
NOT_YET_RECRUITING
Investigational Site, Edmonton
RECRUITING
Investigational Site, Fredericton
RECRUITING
Investigational Site, Markham
RECRUITING
Investigational Site, Mississauga
RECRUITING
Investigational Site, Peterborough
NOT_YET_RECRUITING
Investigational Site, Toronto
RECRUITING
Investigational Site, Toronto
RECRUITING
Investigational Site, Toronto
RECRUITING
Investigational Site, Montreal
RECRUITING
Investigational Site, Québec
NOT_YET_RECRUITING
Investigational Site, Wroclaw
NOT_YET_RECRUITING
Investigational Site, Wroclaw
NOT_YET_RECRUITING
Investigational Site, Lublin
NOT_YET_RECRUITING
Investigational Site, Warsaw
NOT_YET_RECRUITING
Investigational Site, Gdansk
NOT_YET_RECRUITING
Investigational Site, Katowice
NOT_YET_RECRUITING
Investigational Site, Sosnowiec
NOT_YET_RECRUITING
Investigational Site, Krakow
NOT_YET_RECRUITING
Investigational Site, Lodz
Lead Sponsor
Apogee Therapeutics, Inc.
INDUSTRY